Shingrix (Herpes Zoster vaccine Recombinant, adjuvanted)

Product menu

Shingles is a painful disease that can have serious and long lasting complications.1

  • NA

    Post Herpetic Neuralgia (PHN)

    • Affects up to 20% of people ≥50 with shingles.4 PHN is defined as pain present for 90 days or more after HZ rash and is the most common complication of shingles.2 On average it lasts 3-6 months, but can persist for longer.5

    Other complications may occur

    • Ophthalmic: Herpes Zoster ophthalmicus affect approximately 10-20% of patients with shingles.6
    • Dermatological: Bacterial super infection scarring.1
    • Visceral/disseminated disease (rare) affecting lungs, liver, gut and brain.1
    NA

    Note: Immunocompromised patients may suffer more severe and longer lasting complications from shingles.5 Please explore the immunocompromised section for more information

  • US data

    NA

    This chart has been independently created by GSK, using data adapted from Harpaz et al. 2008.7 Data from US populations.

    UK data

    1 in 4 people in the UK will suffer from shingles in their lifetime.5
    90% of adults in the UK are infected with VZV, which causes shingles.8

    Note: Immunocompromised individuals are at increased risk of developing shingles vs the general population.5 Please explore the immunocompromised section for more information

  • NA

    Graph based on data from Drolet et al 2010. The Zoster Brief Pain Inventory measures how much HZ pain interferes with activities of daily life. The above %'s are from 261 newly diagnosed patients with acute HZ pain reporting scores ≥5/10 (substantial interference)

    NA

    Graph based on data from Drolet et al 2010. Impact of PHN on health-related quality of life. Shown are the percentages of participants with PHP (n=63) who reported problems in the EuroQol EQ-5D domains at 90 days after rash onset (the start of the PHN) and at 180 days after rash onset. Error bars = 95% confidence intervals

SHINGRIX is formulated to help protect against shingles.9,10

Discover SHINGRIX

Prescribing information (GB)

Download

Prescribing information (NI)

Download

Summary of product characteristics & Patient information leaflet (GB)

open

Summary of product characteristics & Patient information leaflet (NI)

open

References:

  1. UK NICE Clinical Knowledge Summaries (Shingles) August 2021
  2. Johnson RW, et al. BMC Med. 2010 Jun;8:37
  3. Drolet M et al. CMAJ. 2010; 182(16): 1731–1736
  4. Gauthier A, Breuer J, Carrington D et al. (2009) Epidemiol Infect 137(1): 38-47
  5. The GreenBook chapter 28a – Shingles. July 2023
  6. Johnson RW;Therapeutic advances in vaccines;2015;3;109-20
  7. Harpaz 2008 – CDC MMWR Prevention of Herpes Zoster
  8. DH Green Book ch 34 – Varicella, pg 422. August 2015
  9. SHINGRIX. Summary of Product Characteristics (GB)
  10. SHINGRIX, Northern Ireland Summary of Product Characteristics (SPC)

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

SHINGRIX is owned by or licensed to the GSK group of companies.
© 2024 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

January 2024 | PM-GB-SGX-WCNT-230007(v2.0)